These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
661 related articles for article (PubMed ID: 20382248)
1. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248 [TBL] [Abstract][Full Text] [Related]
2. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185 [TBL] [Abstract][Full Text] [Related]
3. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]
4. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation]. Zhou Z; Wang M; He Y Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
7. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150 [TBL] [Abstract][Full Text] [Related]
8. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397 [TBL] [Abstract][Full Text] [Related]
9. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300 [TBL] [Abstract][Full Text] [Related]
11. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644 [TBL] [Abstract][Full Text] [Related]
12. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238 [TBL] [Abstract][Full Text] [Related]
13. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation. Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704 [TBL] [Abstract][Full Text] [Related]
14. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338 [TBL] [Abstract][Full Text] [Related]
15. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214 [TBL] [Abstract][Full Text] [Related]
16. Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias. Bunin N; Aplenc R; Grupp S; Pierson G; Monos D Bone Marrow Transplant; 2006 Jan; 37(2):143-9. PubMed ID: 16284615 [TBL] [Abstract][Full Text] [Related]
17. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582 [TBL] [Abstract][Full Text] [Related]
18. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Singhal S; Powles R; Treleaven J; Kulkarni S; Sirohi B; Horton C; Millar B; Shepherd V; Tait D; Saso R; Rowland A; Long S; Mehta J Bone Marrow Transplant; 2000 Sep; 26(5):489-96. PubMed ID: 11019837 [TBL] [Abstract][Full Text] [Related]
19. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507 [TBL] [Abstract][Full Text] [Related]
20. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]